Cardiff Oncology, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Cardiff Oncology amended its certificate of incorporation on October 22, 2026, increasing authorized shares to 320M (300M common, 20M preferred). Simultaneously, the company appointed Dr. Leila Alland as interim Chief Medical Officer, replacing Dr. Roger Sidhu. The company is preparing to initiate a Phase 3 registrational trial in onvansertib for RAS-mutated metastatic colorectal cancer in Q1 2027; median PFS has not been reached in the Phase 2 trial's primary arm.
Why this rating
Share increase is routine and dilution-enabling; CMO transition is standard. Phase 3 initiation on schedule is positive operationally but not quantified financially. No material contract, financing, or near-term revenue disclosed.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.